Peer-influenced content. Sources you trust. No registration required. This is HCN.

Letrozole Pre-Surgery Yields Drastic Biomarker Changes in ER+ DCIS

According to a study featured in the Journal of Clinical Oncology, pre-surgery letrozole led to significant imaging and biomarker changes in postmenopausal patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) in a phase 2 clinical trial.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form